SEARCH RESULTS FOR:

Stephen Keith

PRESIDENT, GROWMAX RESOURCES
MINPER - PERUMIN Official Investment Guide 2017
Recently re-branded GrowMax Resources explains how it intend to develop its fertilizer assets in Peru.

Gold Mining in Western Australia

Western Australia Mining 2017 Pre-Release
A stable gold price and more efficient extraction and processing techniques have led to a renewed interest in Western Australia.

Yukon: A stampede of Gold Hunters

British Columbia, Yukon and Vancouver Mining 2017
All of a sudden majors and juniors alike are snapping up properties in Yukon.

Dr. Hany Moustapha

PROFESSOR AND DIRECTOR, AÉROÉTS & ENIOR RESEARCH FELLOW PWC
Québec Aerospace 2017
École de technologie supérieure (ÉTS) is Canada’s leading university when it comes to aerospace graduating 750-800 engineers each year.

Gilles Labbé

PRESIDENT & CEO, HÉROUX-DEVTEK
Québec Aerospace 2017
Héroux-Devtek continues to grow its landing gear business with its contract for Boeing’s 777.

Québec’s Aerospace 4.0: A Solution to Cost Pressures?

Québec Aerospace 2017
As cost pressures propagate from OEM’s down the value chain, does Industry 4.0 hold the solutions?

Dale Clayton

MANAGING DIRECTOR, LIEBHERR
Chile Mining 2018 Expomin Official Investment Guide
Lieberr sees Chile as a good opportunity to diversify its commodity exposure and is building a firm presence there.

Ivan Rayo

GENERAL MANAGER, JRI INGENIERÍA
Chile Mining 2018 Expomin Official Investment Guide
Chilean engineering company JRI describes how experience and innovation have helped the company to expand.

Christian Kopfli

CEO, CHROMOCELL
United States Biopharmaceuticals 2017
Chromocell is using its own Chrmovert technology to provide alternative pain blockers to opioids.

Renold Capocasale

CEO, FLOWMETRIC INC.
United States Biopharmaceuticals 2017
FlowMetric offers scientific analysis using Flow Cytometry to advance drug development.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS